Melanotan-II

The Cancer Association of South Africa (CANS) noted with concern the availability and illegal sale and distribution of a dangerous sunless tanning product (Melanotan II). CANS would like to warn the public against this product. Melanotan-II is a dangerous laboratory-made chemical that is similar to a hormone found in humans called melanocyte-stimulating hormone (MSH). Care should be taken not to confuse Melanotan-II with melatonin.

Melanotan-II has been used to produce erections in men with erectile dysfunction (ED), and lately also to tan the skin without exposure to the sun (sunless tanning). Please refer to the Fact Sheet and Position Statement on Sunless Tanning for additional information about this dangerous product – The Fact Sheet and Position Statement on Sunless Tanning can be found on CANS’s website at www.cansa.org.za.

Melanotan-II is similar to a substance found in our bodies, called “melanocyte-stimulating hormone” (MSH), which increases the production of skin-darkening pigments.

Melanotan-II is thought to work on the brain to stimulate erections in men.

Melanotan-II is possibly safe when used under medical supervision for treating erectile dysfunction. There is, however, insufficient information to know whether it is at all safe for other uses. Adverse effects which may occur with the use of Melanotan-II include nausea, stomach cramps, decreased appetite, flushing, tiredness, yawning, darkened skin, spontaneous erections of the penis, and other side effects.

Cases of malignant melanoma (the most dangerous type of skin cancer) have been scientifically described following the use of Melanotan-II.

Women who are pregnant or breastfeeding should not use Melanotan-II at all.

Disclaimer
This warning is intended to provide general information only and, as such, should not be considered as a substitute for advice, medically or otherwise, covering any specific situation. Users should seek appropriate advice before taking or refraining from taking any action in reliance on any information contained in this document. So far as permissible by law, the Cancer Association of South Africa (CANS) does not accept any liability to any person (or his/her dependants/estate/heirs) relating to the use of any information contained in this document.

Whilst CANS has taken every precaution in compiling this document, neither it, nor any contributor(s) to this document can be held responsible for any action (or the lack thereof) taken by any person or organisation wherever they shall be based, as a result, direct or otherwise, of information contained in, or accessed through, this document.